Does REMIMAZOLAM Cause Vascular access site occlusion? 11 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Vascular access site occlusion have been filed in association with REMIMAZOLAM (BYFAVO). This represents 8.0% of all adverse event reports for REMIMAZOLAM.
11
Reports of Vascular access site occlusion with REMIMAZOLAM
8.0%
of all REMIMAZOLAM reports
0
Deaths
0
Hospitalizations
How Dangerous Is Vascular access site occlusion From REMIMAZOLAM?
Of the 11 reports.
Is Vascular access site occlusion Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for REMIMAZOLAM. However, 11 reports have been filed with the FAERS database.
What Other Side Effects Does REMIMAZOLAM Cause?
Anaphylactic shock (21)
Anaphylactic reaction (11)
Cardiac arrest (10)
Hypotension (10)
Oxygen saturation decreased (9)
Blood pressure decreased (8)
Off label use (8)
Bronchospasm (6)
Circulatory collapse (6)
Drug ineffective (6)
What Other Drugs Cause Vascular access site occlusion?
Which REMIMAZOLAM Alternatives Have Lower Vascular access site occlusion Risk?
REMIMAZOLAM vs REMODULIN
REMIMAZOLAM vs REPAGLINIDE
REMIMAZOLAM vs REPOTRECTINIB
REMIMAZOLAM vs REQUIP
REMIMAZOLAM vs RESLIZUMAB